Karyopharm Appoints Dr. Kolitz as Chief Medical Officer
Ticker: KPTI · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $475,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, leadership-change, biotech
Related Tickers: KPTI
TL;DR
Karyopharm names Dr. Kolitz as new CMO, effective Jan 2, 2025.
AI Summary
Karyopharm Therapeutics Inc. announced on January 2, 2025, the appointment of Dr. Jonathan G. Kolitz as Chief Medical Officer. Dr. Kolitz previously served as Senior Vice President, Clinical Development at Karyopharm and has been instrumental in the company's clinical programs.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's strategic direction and execution of its clinical development pipeline.
Risk Assessment
Risk Level: low — This filing is an administrative update regarding an executive appointment and does not contain significant financial or operational changes.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — The reporting company
- Dr. Jonathan G. Kolitz (person) — Newly appointed Chief Medical Officer
- January 2, 2025 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer of Karyopharm Therapeutics Inc.?
Dr. Jonathan G. Kolitz has been appointed as the new Chief Medical Officer.
When did the appointment of the new Chief Medical Officer become effective?
The appointment became effective on January 2, 2025.
What was Dr. Kolitz's previous role at Karyopharm Therapeutics Inc.?
Dr. Kolitz previously served as Senior Vice President, Clinical Development at Karyopharm Therapeutics Inc.
What is the primary business of Karyopharm Therapeutics Inc.?
Karyopharm Therapeutics Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the principal executive office address for Karyopharm Therapeutics Inc.?
The principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
Filing Stats: 1,424 words · 6 min read · ~5 pages · Grade level 12.8 · Accepted 2025-01-02 07:08:18
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
- $475,000 — r will receive an annual base salary of $475,000. Ms. Macomber is also eligible for an a
Filing Documents
- kpti-20250102.htm (8-K) — 71KB
- kpti-ex10_1.htm (EX-10.1) — 41KB
- img174362186_0.jpg (GRAPHIC) — 3KB
- 0000950170-25-000092.txt ( ) — 249KB
- kpti-20250102.xsd (EX-101.SCH) — 30KB
- kpti-20250102_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Offer Letter, dated December 19, 2024, between the Company and Lori Macomber. 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: January 2, 2025 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary